Eluvia Meta-Analysis
Eluvia DES demonstrated consistently greater primary patency and TLR outcomes at 12 and 24 months compared with Zilver PTX, Viabahn covered stent and self-expanding nitinol stents (including interwoven stents) with no difference in mortality rates.
Paclitaxel Devices for Femoropopliteal Disease Presented at Charing Cross 2025
Prof. Andrew Holden, Prof. Gunnar Tepe, and Prof. Giovanni Torsello describe the performance of stenting in femoropopliteal disease.
Performance of stenting in femoropopliteal disease:
Systemic review and meta-analysis of proportions
Primary patency
Target lesion revascularization
Eluvia DES is the definitive treatment choice for long, complex lesions.
Additionally, in contrast to comparative stents, Eluvia DES Primary Patency rates remained superior compared with all other stent types and did not decline in long lesions (>150mm) at 12 and 24 months.
12-Month primary patency
Short & long lesions
24-Month primary patency
Short & long lesions
References:
Holden, A. Performance of Stenting in Femoropopliteal Disease: Systematic Literature Review and Meta-analysis of Proportions. Presented at Charing Cross 2025.